Categories: News

Cyberliver Announces Poster Presentation of AlcoChange, Pilot Study at The Liver Meeting 2018

Cyberliver reports a positive pilot study of AlcoChange, a patented Smartphone Tool and Behavioural Intervention Platform to Reduce Alcohol Consumption in Alcohol-Related Liver Disease. The data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life.

London, United Kingdom, November 12, 2018 –(PR.com)– Cyberliver Ltd., a developer of cutting edge solutions for liver care, today announced that Dr Gautam Mehta and team will present a poster at The Liver Meeting 2018 of the American Association for the Study of Liver Diseases held on Friday, November 9th through Tuesday, November 13th, at the Moscone North and South Convention Centre in San Francisco.

The poster is entitled: �AlcoChange: A Pilot Study of a Smartphone Tool to Reduce Alcohol Consumption in Alcohol-Related Liver Disease (Poster #1398)” will be presented on Sunday, November 11 2018, between 8:00 AM and 5:30 PM at Hall C – Poster Hall.

Dr. Gautam Mehta, Clinical Lead of the study, Consultant and Senior Lecturer in Hepatology at Royal Free Hospital said, “We are delighted to be presenting this study at The Liver Meeting 2018. The data demonstrate the potential of digital tools like AlcoChange to help manage alcohol-related liver disease (ARLD).” The AlcoChange clinical study, which ran from spring 2015 to end of 2017 at Royal Free London NHS Trust, supported by The Health Foundation and led by Prof. Kevin Moore and Dr. Gautam Mehta, clearly demonstrated that a smartphone app/breathalyzer can be used for self-monitoring and for Behavior Change Interventions (BCIs) in patients with ARLD, with a clear “dose response” amongst compliant patients. “Smartphone apps are a scalable intervention to help maintain abstinence in ARLD.”

Commenting on the study, Prof. Rajiv Jalan, Clinician Scientist, Prof. of Hepatology, Head of Liver Failure group at UCL said, “The data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life.”

About Cyberliver:
Cyberliver is a company that focuses on delivering cutting edge solutions for liver care via use of innovative technology, based out of London, England, UK.

About AlcoChange:
AlcoChange is a patented Smartphone App/Breathalyzer platform, allows the monitoring of craving, alcohol consumption and breath alcohol, and provides motivational messaging in response to patient triggers.

For AlcoChange and Cyberliver Contact:
Ravi Kumar, ravi.kumar@Cyberliver.com
First Floor, Burnells, 5 Garland Road, Stanmore, Middlesex, HA7 1NR, United Kingdom

Let’s block ads! (Why?)

Miscw.com

Recent Posts

Cooler Master Unveils New CALIBER X2C and R3C Gaming Chairs for the Ultimate Cool Comfort

Stay Cool and Comfortable, Whatever the Game Throws at You TAIPEI, Taiwan--(BUSINESS WIRE)--Cooler Master, a…

2 hours ago

Philippines International (Inbound/Outbound) Remittance Business Report 2024: Analysis by Transaction Value & Volume, Inbound and Outbound Transfers to and from Key States, Demographics 2019-2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Philippines International Remittance Market Business and Investment Opportunities - Analysis by Transaction Value…

5 hours ago

PKSHA develops advanced Large Language Models in collaboration with Microsoft Japan

Featuring rapid communication capabilities, this new LLM generates answers 3 times faster than conventional LLMs,…

5 hours ago

Global Isobutane Industry Report 2024: Market Analysis, Size, Share, Growth, Trends, and Forecasts to 2031 with Focus on China and India – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Isobutane Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031…

5 hours ago